Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$63,453.00+0.17%ETH$1,885.88+0.48%GOLD$4,412.00-0.19%OIL$81.08-0.21%
Smart Investors Daily
Sign InSign Up Free
PO

NASDAQ · POAI

Predictive Oncology Inc.

Healthcare · Medical - Instruments & Supplies

$4.91

Up+$0.29 (+6.28%)

Updated Aug 13, 2026, 11:07 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.99M
P/E ratio
-5.11
Dividend yield
0.00%
52-week range
— – —
Volume
19.09K
Avg. volume
104.1K

Price performance

POAI price history

1M range · 0 trading sessions · Daily adjusted prices

POAI does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest POAI news

The latest Smart Investors Daily articles mentioning POAI.

Stock researchCompany · Overview

POAI research

Overview

Company profile and research snapshot.

Company profile

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$3.06
Implied upside
—
Analysts
6
POAI recent ratings
DateFirmRatingTarget
Nov 15, 2024HC Wainwright & Co.Neutral—
Aug 19, 2024HC Wainwright & Co.Buy—
Jun 30, 2021HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Nov 17, 2025

Predictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks Transcript

Predictive Oncology Inc. ( POAI ) Q3 2025 Earnings Call November 17, 2025 9:00 AM EST Company Participants Raymond Vennare - CEO & Chairman Joshua Blacher - Interim Chief Financial Officer Thomas McLaughlin Kyle Okamoto Presentation Operator Before we begin, let me quickly remind you that during the course of this presentation, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By